Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2023 Earnings Call Transcript

Page 5 of 5

Jones, if you’re not quite ready for this treatment, we’ve got several other options for you here that might be more appealing. And while they don’t do the same thing that the more expensive treatment does, we can still give you some relief — and may be relief from your migraine headaches, your TMD pain, your congested nasal passages — there’s a number of different ways in which the patients can be benefited at a much lower price point. So instead of that patient walking out the door feeling like they couldn’t afford the treatment, now they walk out the door with having spent $1,500 to $3,500 and it’s affordable. And it’s — again, it might not do everything, but it’s going to the patient a long way to being better. So we feel very good about that.

Our provider network is very excited about this. There’s a buzz out there around the pod and what its potential is. We have started some research at some universities with the pod. We’re in the process of starting that right now, as I mentioned. And so we’ve got some very exciting things to come on that. But I think it’s the ability to offer a very cost effective treatment protocol or treatment modality that will actually make the difference for our doctors. It gives them something else to deal with patients who may not yet be ready to afford or pay for. Even with insurance benefits, there’s still an out of pocket portion there. And it just gives them an alternative. So I think that we’re going to see some — and that’s rolling out even as we speak.

That’s being rolled out right now. We finished our training, preparations with videos, online training, all of the resource materials that needed to be done and created for that. And now it’s been rolled out to our provider network. So again, Q3-Q4, you’re going to start to see the impact of the new product lines more fully realized in Q3 and Q4.

Lucas Ward : Okay, great. Thank you very much.

Kirk Huntsman : Okay.

Operator: Ladies and gentlemen, there are no further questions at this time. I’d like to turn the call back over to management for closing remarks.

Kirk Huntsman: Well, thank you, everyone, for being here today. We, as you can probably tell, we feel like this is an exciting time in our history. We truly believe that someday we’ll look back and see this particular time as a watershed moment in the history of this company. And we’re excited about what the future holds in store. We appreciate all of your support and the patience you’ve had as we’ve gotten to this point. We look forward to sharing our continued progress with you in the future. So thank you very much, and have a great evening.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.

Follow Vivos Therapeutics Inc.

Page 5 of 5